Primary Biliary Cholangitis (PBC) - Market Insights, Epidemiology and Market Forecast-2027

Albany, NY -- (SBWire) -- 01/28/2019 --Primary Biliary Cholangitis (PBC) - Market Insights, Epidemiology and Market Forecast-2027

28 Jan. 19

Approximately 7–11% of PBC patients are males.

1. Primary Biliary Cholangitis (PBC) is a chronic, progressive liver disorder that mostly affects women and usually appears during middle age. It leads to inflammation and scarring of the small bile ducts. If PBC is untreated, it can lead to cirrhosis, or scarring of the entire liver, which can lead to liver failure.
2. PBC is common among women of middle age worldwide. The disease ratio among female to male is 9:1.
3. In the UK, the prevalence of PBC is estimated to be 12.9 per 100,000 population, of which 90% of the cases were reported in women.
4. Epidemiological studies have also revealed the prevalence of PBC to be around 27–54 per million cases in Japan.

(Albany, US) DelveInsight launched a new report on Primary Biliary Cholangitis (PBC) - Market Insights, Epidemiology and Market Forecast-2027
Key topics covered

1. The Primary Biliary Cholangitis epidemiology division provides the insights about the historical and current patient pool and forecasted trend for every 7 major countries.
2. The report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
3. The market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
4. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

"In 2016, the prevalence of PBC in the U.S. was estimated to vary from 1.91 to 40.2 per 100,000 persons"
The overall survival rates without liver transplantation were 84% and 66% at 10 and 20 years respectively. In early-stage patients, 6% and 22% were predicted to progress to liver transplantation or death after 10 and 20 years."

There may be a genetic component to the development of PBC since a person with the disease is likely to have a family member also afflicted. The complications of Primary Biliary Cholangitis develop as the ability of the liver to function decreases.

Currently, there is no cure for PBC. The main aim in the management of PBC is to reverse injury from bile duct inflammation, improve the symptoms, slow down the progression of the disease, improve liver biochemistry and improve long-term consequences of chronic cholestasis, such as pruritus, fatigue, osteoporosis and fat-soluble vitamin deficiencies.

Companies covered

1. CymaBay Therapeutics
2. Fast Forward Pharmaceuticals
3. Arena Pharmaceuticals
4. Enanta Pharmaceuticals
5. Genkyotex
And many others

Drugs covered

1. Seladelpar
2. FFP104
3. Etrasimod
4. EDP-305
5. GKT831
And many others

Table of contents

1. Report Introduction
2. Primary Biliary Cholangitis (PBC) Market Overview at a Glance
3. Disease Background and Overview: Primary Biliary Cholangitis (PBC)
4. Epidemiology and Patient Population
5.1. United States
5.2. EU-5
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. Spain
5.2.5. United Kingdom
5.3. Japan
5.3.1. Prevalent cases of Primary Biliary Cholangitis (PBC) (2016-2027)
5.3.2. Gender specific prevalence of Primary Biliary Cholangitis (PBC)
5.3.3. Diagnosed and Treatable Cases of Primary Biliary Cholangitis (PBC)
6. Treatment & Medical Practices
7. Marketed drugs
7.1. Ursodeoxycholic acid: Axcan Pharma
7.2. Obeticholic acid: Intercept Pharmaceuticals
8. Emerging Therapies
8.1. Key Cross Competition
8.2. Seladelpar: CymaBay Therapeutics
8.3. Etrasimod: Arena Pharmaceuticals
8.4. FFP104: Fast Forward Pharmaceuticals
9. Primary Biliary Cholangitis (PBC): Market Size
9.1. Key Findings
9.2. Total 7MM Primary Biliary Cholangitis (PBC) Market Analysis
10. 7MM Primary Biliary Cholangitis (PBC): Country-Wise Market Analysis
10.1. United States
10.2. Germany
10.3. France
10.4. United Kingdom
10.5. Spain
10.6. Italy
10.7. Japan
11. Report Methodology
12. DelveInsight Capabilities
13. Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight